793 related articles for article (PubMed ID: 11320369)
1. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
[TBL] [Abstract][Full Text] [Related]
2. Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan.
Gremmler B; Kunert M; Schleiting H; Ulbricht LJ
Eur J Heart Fail; 2000 Jun; 2(2):183-7. PubMed ID: 10856732
[TBL] [Abstract][Full Text] [Related]
3. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
[TBL] [Abstract][Full Text] [Related]
4. Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure.
Hollenberg NK
Curr Hypertens Rep; 2001 Sep; 3 Suppl 1():S25-8. PubMed ID: 11580885
[TBL] [Abstract][Full Text] [Related]
5. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
Brodsky S; Gurbanov K; Abassi Z; Hoffman A; Ruffolo RR; Feuerstein GZ; Winaver J
Hypertension; 1998 Oct; 32(4):746-52. PubMed ID: 9774374
[TBL] [Abstract][Full Text] [Related]
6. Effects of eprosartan versus enalapril in hypertensive patients on the renin-angiotensin-aldosterone system and safety parameters: results from a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group.
Gavras I; Gavras H
Curr Med Res Opin; 1999; 15(1):15-24. PubMed ID: 10216807
[TBL] [Abstract][Full Text] [Related]
7. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
Mitrovic V; Willenbrock R; Miric M; Seferovic P; Spinar J; Dabrowski M; Kiowski W; Marks DS; Alegria E; Dukát A; Lenz K; Arens HA
Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
[TBL] [Abstract][Full Text] [Related]
9. Add-on angiotensin receptor blockade with maximized ACE inhibition.
Agarwal R
Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
[TBL] [Abstract][Full Text] [Related]
10. Central inhibition of AT1receptors by eprosartan--in vitro autoradiography in the brain.
Muders F; Palkovits M; Bahner U; Kirst I; Elsner D; Jandeleit-Dahm K
Pharmacol Res; 2001 Mar; 43(3):251-5. PubMed ID: 11401417
[TBL] [Abstract][Full Text] [Related]
11. Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure.
Suzuki G; Mishima T; Tanhehco EJ; Sharov VG; Todor A; Rostogi S; Gupta RC; Chaudhry PA; Anagnostopoulos PV; Nass O; Goldstein S; Sabbah HN
Br J Pharmacol; 2003 Jan; 138(2):301-9. PubMed ID: 12540520
[TBL] [Abstract][Full Text] [Related]
12. Management of hypertension: the advent of a new angiotensin II receptor antagonist.
Hedner T
J Hypertens Suppl; 1999 Jun; 17(2):S21-5. PubMed ID: 10465063
[TBL] [Abstract][Full Text] [Related]
13. Clinical profile of eprosartan.
Puig JG; López MA; Bueso TS; Bernardino JI; Jiménez RT;
Cardiovasc Drugs Ther; 2002 Dec; 16(6):543-9. PubMed ID: 12766389
[TBL] [Abstract][Full Text] [Related]
14. Effects of different AT1-receptor antagonists in the therapy of severe heart failure pretreated with ACE inhibitors.
Gremmler B; Kisters K; Kunert M; Schleiting H; Ulbricht LJ
Acta Cardiol; 2007 Aug; 62(4):321-8. PubMed ID: 17824291
[TBL] [Abstract][Full Text] [Related]
15. Effects of angiotensin II receptor antagonists on [(123)I]metaiodobenzylguanidine myocardial imaging findings and neurohumoral factors in chronic heart failure.
Shinohara H; Fukuda N; Soeki T; Sakabe K; Onose Y; Tamura Y
Heart Vessels; 2002 Dec; 17(2):47-52. PubMed ID: 12541093
[TBL] [Abstract][Full Text] [Related]
16. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.
Leu HB; Charng MJ; Ding PY
Jpn Heart J; 2004 Jul; 45(4):623-35. PubMed ID: 15353873
[TBL] [Abstract][Full Text] [Related]
17. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure.
Havranek EP; Thomas I; Smith WB; Ponce GA; Bilsker M; Munger MA; Wolf RA
J Am Coll Cardiol; 1999 Apr; 33(5):1174-81. PubMed ID: 10193713
[TBL] [Abstract][Full Text] [Related]
18. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
Levine B
Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
[TBL] [Abstract][Full Text] [Related]
19. AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.
Heusser K; Vitkovsky J; Schmieder RE; Schobel HP
Auton Neurosci; 2003 Aug; 107(1):45-51. PubMed ID: 12927226
[TBL] [Abstract][Full Text] [Related]
20. [Hemodynamic and humoral effects of parenteral therapy with intravenously administered ACE inhibitor quinaprilat in patients with advanced heart failure].
Mitrovic V; Mudra H; Bonzel T; Schmidt W; Schlepper M
Z Kardiol; 1996 Nov; 85(11):828-38. PubMed ID: 9064945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
